PHILADELPHIA — Timothy Crew, former chief executive officer of Cipla North America, is joining Lannett Co. as CEO. Plans call for Crew to take the CEO reins at effective Jan. 2, Lannett said. He also is slated to be appointed as a board director after the company’s 2018 annual shareholders meeting. Crew succeeds Arthur Bedrosian,
PHILADELPHIA — Lannett Co. has entered into an agreement with Aralez Pharmaceuticals Trading DAC, an Irish designated activity company, to become the exclusive U.S. distributor for metoprolol succinate extended-release tablets, a cardiovascular medication. Financial terms weren’t disclosed. Lannett said late Wednesday that its metoprolol succinate product — available in dosages of 25 mg, 50 mg,
PHILADELPHIA — Lannett Co. has launched a search for a new chief executive officer to succeed Arthur Bedrosian, who plans to step down. Lannett said Monday that its board of directors has retained a leading executive search firm to identify potential candidates to take the CEO reins from Bedrosian, who has agreed to serve in
PHILADELPHIA — Lannett Co. has received Food and Drug Administration approval for 20-mg and 40-mg esomeprazole magnesium delayed-release capsules, an antacid. Lannett said its esomeprazole product is a generic version of Nexium delayed-release capsules (20 mg and 40 mg), aka “the purple pill,” from AstraZeneca Pharmaceuticals. A proton pump inhibitor, esomeprazole decreases the amount of acid in
PHILADELPHIA — Lannett Co. has received Food and Drug Administration approval for niacin extended-release tablets 500 mg and 1,000 mg and amantadine hydrochloride capsules 100 mg. Lannett said Monday that its niacin product is a generic version of Niaspan ER tablets (500 mg and 1,000 mg) from AbbVie Inc. The medication is indicated to raise
PHILADELPHIA — Lannett Co. has gained Food and Drug Administration approval for levocetirizine dihydrochloride oral solution, 2.5 mg/5 ml (0.5 mg/ml), an allergy medication. Lannett said its product is a generic version of Xyzal Oral Solution 2.5 mg/5 ml (0.5 mg/ml) from UCB Inc. Plans call for levocetirizine dihydrochloride oral solution to be manufactured in
PHILADELPHIA — Lannett Co. has gained Food and Drug Administration approval for metaxalone tablets 800 mg, a muscle relaxant. Lannett said Monday that its product is a generic version of Skelaxin tablets (800 mg) from King Pharmaceuticals Inc. Metaxalone alleviates musculoskeletal pain by blocking nerve impulses in the brain. “Metaxalone tablets, indicated as an adjunct
PHILADELPHIA — Lannett Co. has been cleared by the Food and Drug Administration to market paroxetine extended-release tablets, an antidepressant, in strengths of 12.5 mg, 25 mg and 37.5 mg. The company said its product, a generic version of Paxil CR extended-release tablets (12.5 mg, 25 mg and 37.5 mg) from Apotex Technologies, has begun
PHILADELPHIA — Lannett Co. has gained approval from the Food and Drug Administration for neomycin sulfate tablets 500 mg, an antibiotic. Lannett said Monday that its product is a therapeutic equivalent to the reference listed drug, neomycin sulfate tablets (500 mg) from Teva Pharmaceuticals USA Inc. “The approval for neomycin sulfate Tablets expands our portfolio
PHILADELPHIA — Lannett Co. plans to co-develop a generic insulin pharmaceutical product for the U.S. market with YiChang HEC ChangJiang Pharmaceutical Co. Ltd., its strategic partner in China. Lannett said Friday that holds the exclusive U.S. marketing rights to the product, which currently is in late-stage development. The company will manage the remaining clinical and
PHILADELPHIA — Michael Bogda, president of Lannett Co., plans to leave the company to pursue other interests. Lannett, which announced the move late Monday, said that Bogda is slated to depart on June 3. In February, Lannett said Bogda was leading a team to implement its restructuring plan, focusing on streamlining operations and cost reduction.
PHILADELPHIA — Lannett Co. has received Food and Drug Administration approvals for a pair of new generic products. Abbreviated New Drug Applications (ANDAs) have been approved for potassium chloride extended-release capsules, in strengths of 8 mEq and 10 mEq, and for temozolomide capsules, in dosages of 5 mg, 20 mg, 100 mg, 140 mg, 180
PHILADELPHIA — Lannett Co. has received approval from the Food and Drug Administration for sumatriptan nasal spray (5 mg/spray and 20 mg/spray), a treatment for migraine headaches. Lannett said its product is a generic version of Imitrex nasal spray from GlaxoSmithKline. “We believe our sumatriptan nasal spray (USP, 5 mg/spray and 20 mg/spray) will be
PHILADELPHIA — Lannett Co. has instituted a restructuring plan to streamline operations, sharpen efficiencies and trim costs. Announced this week, the plan is part of the generic drug maker’s efforts to integrate its recently completed acquisition of Kremers Urban Pharmaceuticals Inc. Lannett said actions are already under way and include the closing of Kremers Urban’s
